Further analysis finds Oxford-AstraZeneca COVID-19 vaccine 76 percent effective 3 months after first shot


Further analysis of trial data for the COVID-19 vaccine developed by the University of Oxford and AstraZeneca appears to have provided a boost for the United Kingdom's plan to lengthen the interval between doses to up to 12 weeks, which allows the country to administer the initial shot to more people. The U.K.'s decision is at the center of a wider debate over whether governments should prioritize of partially inoculating a larger percentage of the population or save second doses and give fewer people complete protection.
The latest update to the study, which hasn't been peer-reviewed yet, suggests the vaccine is 76 percent effective at preventing symptomatic COVID-19 infections up to three months after a singular dose. That level of immunity appears to kick in a little more than three weeks after the initial shot, with little evidence of protection waning in the interim period. The figure then rises to 82 percent after the second dose.
Swabs taken weekly from volunteers in the U.K. (the study also included participants in Brazil and South Africa) also showed a 67 percent reduction in positive PCR tests, raising confidence the vaccine may help prevent transmission as opposed to just lowering the risk of symptomatic and severe infections, though further study is necessary on that front. Read more at BBC and Bloomberg.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
Exurbs: America's biggest housing trend you haven't heard of
Under the Radar Northeastern exurbs were the nation's biggest housing markets in 2024
-
How to enjoy a coolcation in Sweden
The Week Recommends You won't break a sweat on Lake Asnen or underground at the Adventure Mine
-
Crossword: May 8, 2025
The Week's daily crossword
-
RFK Jr. visits Texas as 2nd child dies from measles
Speed Read An outbreak of the vaccine-preventable disease continues to grow following a decade of no recorded US measles deaths
-
Shingles vaccine cuts dementia risk, study finds
Speed Read Getting vaccinated appears to significantly reduce the chances of developing Alzheimer's and other forms of dementia
-
Measles outbreak spreads, as does RFK Jr.'s influence
Speed Read The outbreak centered in Texas has grown to at least three states and Health Secretary Robert F. Kennedy Jr. is promoting unproven treatments
-
RFK Jr. offers alternative remedies as measles spreads
Speed Read Health secretary Robert F. Kennedy Jr. makes unsupported claims about containing the spread as vaccine skepticism grows
-
Texas outbreak brings 1st US measles death since 2015
Speed read The outbreak is concentrated in a 'close-knit, undervaccinated' Mennonite community in rural Gaines County
-
Mystery illness spreading in Congo rapidly kills dozens
Speed Read The World Health Organization said 53 people have died in an outbreak that originated in a village where three children ate a bat carcass
-
Ozempic can curb alcohol cravings, study finds
Speed read Weight loss drugs like Ozempic and Wegovy may also be helpful in limiting alcohol consumption
-
New form of H5N1 bird flu found in US dairy cows
Speed Read This new form of bird flu is different from the version that spread through herds in the last year